Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
35.7
€ millions (capital stock)Wording
Definitive
How definitive the wording is.This transaction
Acquisition (share acquisition)CounterpartyCorporación Químico-Farmacéutica Esteve, Teijin Holdings Europe BV
Disclosing companyMitsubishi Chemical Group Corporation
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Execution Date / Effective Date3 March 2026 (completion of share acquisition procedures)
Target company
Home healthcare services business
Location Spain (Barcelona)Share capital €35.7 millionDate of incorporation February 2009
Net Sales€40 million (fiscal year ended December 2024)
Operating profit€3 million (fiscal year ended December 2024)
Net income for the current fiscal year€2 million (fiscal year ended December 2024)
Net assets€36 million (fiscal year ended December 2024)
Impact on Business Performance
The acquisition is reflected in the full-year consolidated earnings forecast for the fiscal year ending March 2026, announced on 5 February 2026.
Procedures and assumptions
Management structure after acquisitionThe company changed its name to “Nippon Sanso Homecare España, S.L.U.” The representative is Director Justin Corcho (Mr.). Employee treatment: not disclosed
| Item | Details |
|---|---|
| Transaction name | Acquisition (share acquisition) |
| Counterparty name | Corporación Químico-Farmacéutica Esteve, Teijin Holdings Europe BV |
| Name of the Subject Company | Nippon Sanso Homecare España, S.L.U. (former name: Esteve Teijin Healthcare, S.L.) |
| Business Description of the Subject Company | Home healthcare services business |
| Location of the Subject Company | Spain (Barcelona) |
| Capital Stock of the Subject Company | €35.7 million |
| Date of Establishment of the Subject Company | February 2009 |
| Net Sales of the Subject Company | €40 million (fiscal year ended December 2024) |
| Operating Profit of the Subject Company | €3 million (fiscal year ended December 2024) |
| Net Income of the Subject Company | €2 million (fiscal year ended December 2024) |
| Net Assets of the Subject Company | €36 million (fiscal year ended December 2024) |
| Voting rights ownership percentage | After 100%（Oximesa S.L.U.） (before not disclosed) |
| Impact on Business Performance | The acquisition is reflected in the full-year consolidated earnings forecast for the fiscal year ending March 2026, announced on 5 February 2026. |
| Execution Date / Effective Date | 3 March 2026 (completion of share acquisition procedures) |
| Management structure after acquisition | The company changed its name to “Nippon Sanso Homecare España, S.L.U.” The representative is Director Justin Corcho (Mr.). Employee treatment: not disclosed |
Items this document does not state (17)
Acquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following the acquisition of the shares, the Company reviewed the target company’s past capital transactions and found that its capital stock amounted to at least 10% of the Company’s capital stock, meaning that it qualified as a specified subsidiary.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.